CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
+18.11%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$514M
AUM Growth
+$169M
(+49%)
Cap. Flow
+$116M
Cap. Flow
% of AUM
22.65%
Top 10 Holdings %
Top 10 Hldgs %
26.88%
Holding
503
New
57
Increased
239
Reduced
90
Closed
78
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$6.88M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$6.46M |
| 3 |
Gilead Sciences
GILD
|
+$6.38M |
| 4 |
Amgen
AMGN
|
+$6.24M |
| 5 |
Adobe
ADBE
|
+$5.19M |
Top Sells
| 1 |
NVIDIA
NVDA
|
+$5.18M |
| 2 |
Analog Devices
ADI
|
+$3.75M |
| 3 |
Amazon
AMZN
|
+$3.48M |
| 4 |
lululemon athletica
LULU
|
+$3.4M |
| 5 |
iQIYI
IQ
|
+$1.91M |
Sector Composition
| 1 | Technology | 34.39% |
| 2 | Healthcare | 30.05% |
| 3 | Consumer Discretionary | 17.55% |
| 4 | Communication Services | 6.11% |
| 5 | Consumer Staples | 4.61% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
GE HealthCare
GEHC
$35.9B
| $69.8K | 0.01% |
903
-792
| -47% | -$61.2K |
|
327
Evolus
EOLS
$478M
| $69.6K | 0.01% |
6,614
+5,155
| +353% | +$54.3K |
|
328
Verisk Analytics
VRSK
$37.5B
| $69K | 0.01% |
289
-251
| -46% | -$60K |
|
329
MacroGenics
MGNX
$109M
| $69K | 0.01% |
7,174
+5,577
| +349% | +$53.7K |
|
330
Xcel Energy
XEL
$42.6B
| $68.8K | 0.01% |
1,103
-952
| -46% | -$59.4K |
|
|
MRNS
331
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $68.6K | 0.01% |
6,307
+5,003
| +384% | +$54.4K |
|
332
Baker Hughes
BKR
$44.8B
| $67.8K | 0.01% |
1,985
-1,777
| -47% | -$60.7K |
|
333
Castle Biosciences
CSTL
$715M
| $67.1K | 0.01% |
3,110
+2,421
| +351% | +$52.2K |
|
|
PETQ
334
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $66.6K | 0.01% |
3,372
+2,625
| +351% | +$51.8K |
|
335
Novavax
NVAX
$1.29B
| $66K | 0.01% |
13,743
+11,319
| +467% | +$54.3K |
|
336
Enliven Therapeutics
ELVN
$1.17B
| $65.9K | 0.01% |
+4,763
| New | +$65.9K |
|
337
AnaptysBio
ANAB
$619M
| $65.8K | 0.01% |
3,072
+2,390
| +350% | +$51.2K |
|
338
GlobalFoundries
GFS
$17.8B
| $65.4K | 0.01% |
1,080
-961
| -47% | -$58.2K |
|
339
Zscaler
ZS
$44B
| $65.1K | 0.01% |
294
-250
| -46% | -$55.4K |
|
340
HUTCHMED
HCM
$2.76B
| $65.1K | 0.01% |
3,593
+2,801
| +354% | +$50.7K |
|
341
Theravance Biopharma
TBPH
$693M
| $64.7K | 0.01% |
5,759
+4,402
| +324% | +$49.5K |
|
342
Trade Desk
TTD
$25.6B
| $63.3K | 0.01% |
880
-783
| -47% | -$56.3K |
|
|
ANSS
343
DELISTED
Ansys
ANSS
| $63.1K | 0.01% |
174
-149
| -46% | -$54.1K |
|
344
Allogene Therapeutics
ALLO
$253M
| $62.5K | 0.01% |
19,467
+15,170
| +353% | +$48.7K |
|
345
Tourmaline Bio
TRML
$1.22B
| $61.7K | 0.01% |
+2,357
| New | +$61.7K |
|
346
Ambarella
AMBA
$3.61B
| $61.3K | 0.01% |
1,000
| – | – |
|
347
ARS Pharmaceuticals
SPRY
$1.02B
| $60.9K | 0.01% |
11,105
+8,652
| +353% | +$47.4K |
|
348
Coca-Cola Europacific Partners
CCEP
$41.6B
| $60.7K | 0.01% |
+909
| New | +$60.7K |
|
349
Phathom Pharmaceuticals
PHAT
$914M
| $60.5K | 0.01% |
6,626
+5,171
| +355% | +$47.2K |
|
350
CDW
CDW
$22.1B
| $60.5K | 0.01% |
+266
| New | +$60.5K |
|